A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Traws Pharma, Inc.
TRAW
$4M
Mkt Cap
$0.49
-6.13%
Traws Pharma, Inc. (TRAW) has a 5-year average return on invested capital (ROIC) of -81.9%. This is below average and may indicate limited pricing power.
Traws Pharma, Inc. (TRAW) has a market capitalization of $3M. It is classified as a small-cap stock.
Traws Pharma, Inc. (TRAW) does not currently pay a regular dividend.
Traws Pharma, Inc. (TRAW) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Traws Pharma, Inc. (TRAW) generated $16 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Traws Pharma, Inc. (TRAW) reported earnings per share (EPS) of $0.82 in its most recent fiscal year.
Traws Pharma, Inc. (TRAW) has a return on equity (ROE) of -42.6%. A negative ROE may indicate losses or negative equity.
Traws Pharma, Inc. operates in the Pharmaceutical Preparations industry, Healthcare sector. Full business description from SEC filing not yet available.
| Segment | 2011 | % of Total |
|---|---|---|
SymBio | $8M | 100% |
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 2.8M | - | - | 226K | - | - |
| Net Income | 94M | 6.9M | -167M | - | -19M | -16M |
| EPS | $55.34 | $0.82 | $-35.21 | $-180.56 | $-7.28 | $-7.68 |
| Free Cash Flow | 0 | 16M | -33M | -18M | -16M | -19M |
| ROIC | -100.2% | -133.0% | -450.6% | - | -51.0% | -61.8% |
| Gross Margin | - | 0.0% | - | - | - | - |
| Debt/Equity | 0.00 | -17.88 | -1.79 | 1.13 | 0.39 | 0.20 |
| Dividends/Share | $0.00 | $0.00 | - | - | - | - |
| Operating Income | -16M | -18M | -142M | -20M | -20M | -16M |
| Operating Margin | -554.6% | - | - | -8981.4% | - | - |
| ROE | 2072.4% | -42.6% | - | - | -51.0% | -61.8% |
| Shares Outstanding | 7M | 8M | 5M | 0M | 3M | 2M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | N/A | N/A | N/A | 787K | N/A | N/A | N/A | N/A | N/A | 226K | N/A | N/A | 2.8M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% | N/A |
| R&D | 49M | 26M | 20M | 19M | 17M | 16M | 17M | 7.3M | 11M | 11M | 13M | 12M | 9.0M |
| SG&A | 15M | 9.5M | 9.2M | 7.4M | 7.6M | 8.3M | 8.3M | 9.4M | 8.4M | 9.1M | 12M | 8.5M | 9.7M |
| EBIT | -64M | -24M | -24M | -26M | -23M | -22M | -25M | -16M | -20M | -20M | -142M | -18M | -16M |
| Op. Margin | N/A | N/A | N/A | -3270.3% | N/A | N/A | N/A | N/A | N/A | -8981.4% | N/A | N/A | -554.6% |
| Net Income | -64M | -24M | -20M | N/A | -21M | -22M | -25M | -16M | -19M | N/A | -167M | 6.9M | 94M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 3309.6% |
| Non-Recurring | 0 | -22K | 0 | 0 | 824K | 0 | 1.2M | 1.2M | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||||||||
| ROIC | -123.5% | -146.4% | N/M | N/A | -129.9% | -148.1% | N/M | -61.8% | -51.0% | N/A | N/M | -133.0% | -100.2% |
| ROE | -123.5% | -146.4% | -274.9% | N/A | -381.9% | -253.6% | -283.5% | -61.8% | -51.0% | N/A | N/A | -42.6% | 2072.4% |
| ROA | -83.5% | -67.8% | -84.3% | N/A | -179.7% | -103.4% | -115.2% | -42.8% | -40.0% | N/A | -699.0% | 38.6% | 757.0% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | -58M | -31M | -16M | -24M | -23M | -21M | -23M | -19M | -16M | -18M | -30M | 18M | -19M |
| Free Cash Flow | -58M | -31M | -16M | -24M | -23M | -21M | -23M | -19M | -16M | -18M | -33M | 16M | 0 |
| Owner Earnings | -63M | -35M | -20M | -26M | -24M | -22M | -23M | -20M | -17M | -19M | -31M | 17M | -20M |
| CapEx | 228K | 0 | 0 | 0 | 0 | 55K | 15K | 0 | 0 | 14K | 3.6M | 2.6M | 0 |
| Maint. CapEx | 434K | 150K | 96K | 88K | 55K | 14K | 13K | 14K | 14K | 16K | 12K | 61K | 19K |
| Growth CapEx | 0 | N/A | N/A | N/A | N/A | 41K | 2K | N/A | N/A | 0 | 3.6M | 2.5M | 0 |
| D&A | 434K | 150K | 96K | 88K | 55K | 14K | 13K | 14K | 14K | 16K | 12K | 61K | 19K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% | 0.0% |
| Stock-Based Comp | 5.1M | 3.8M | 3.9M | 1.7M | 1.1M | 1.0M | 369K | 576K | 1.2M | 1.3M | 1.4M | 728K | 735K |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||||||||
| Net Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -6.4M |
| Cash & Equiv. | 44M | 20M | 21M | 4.0M | 17M | 23M | 19M | 55M | 39M | 21M | 21M | 3.8M | 6.4M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | 1.04 | 1.26 | 4.21 | -1.35 | 2.33 | 1.05 | 2.24 | 0.20 | 0.39 | 1.13 | -1.79 | -17.88 | 0.00 |
| Interest Coverage | -31872.0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Equity | 23M | 10M | 4.3M | -12M | 5.4M | 12M | 6.2M | 46M | 28M | 11M | -32M | -629K | 4.5M |
| Total Assets | 47M | 23M | 23M | 5.0M | 18M | 24M | 20M | 55M | 39M | 23M | 25M | 11M | 12M |
| Total Liabilities | 24M | 13M | 18M | 16M | 13M | 12M | 14M | 9.4M | 11M | 12M | 57M | 11M | 7.9M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 2.5M | 2.6M |
| Retained Earnings | -295M | -319M | -338M | -362M | -382M | -403M | -429M | -445M | -464M | -483M | -649M | -640M | -633M |
| Working Capital | 37M | 16M | 13M | -5.1M | 9.3M | 15M | 9.8M | 49M | 31M | 13M | 13M | -3.2M | 1.7M |
| Current Assets | 47M | 23M | 23M | 4.9M | 18M | 23M | 20M | 55M | 39M | 23M | 25M | 8.0M | 9.6M |
| Current Liabilities | 10M | 7.6M | 10M | 10.0M | 8.4M | 8.3M | 10M | 6.1M | 8.0M | 9.2M | 12M | 11M | 7.9M |
| Per Share Data | |||||||||||||
| EPS | -132.30 | -474.30 | -49.95 | -451.69 | -29.94 | -1.16 | -260.40 | -7.68 | -7.28 | -180.56 | -35.21 | 0.82 | 55.34 |
| Owner EPS | -131.19 | -695.73 | -50.38 | -401.35 | -34.78 | -1.18 | -242.80 | -9.54 | -6.71 | -183.27 | -6.60 | 2.08 | -2.84 |
| Book Value | 47.26 | 198.00 | 10.91 | -183.16 | 7.84 | 0.62 | 63.92 | 21.91 | 10.87 | 101.61 | -6.69 | -0.08 | 0.64 |
| Cash Flow/Share | -119.76 | -617.88 | -40.16 | -373.18 | -33.03 | -1.12 | -238.85 | -9.26 | -6.26 | -170.73 | -6.30 | 2.17 | 13.21 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 | 0.00 |
| Shares Out. | 0.5M | 0.1M | 0.4M | 0.1M | 0.7M | 18.5M | 0.1M | 2.1M | 2.6M | 0.1M | 4.7M | 8.4M | 7.1M |
| Valuation | |||||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 3.6 | 2.3 | 10.8 | N/A | 64.3 | 8.4 | 12.7 | 0.9 | 0.5 | 8.8 | N/A | N/A | 0.8 |
| Price/Sales | N/A | N/A | N/A | 242.8 | N/A | N/A | N/A | N/A | N/A | 494.4 | N/A | N/A | 1.2 |
| FCF Yield | -70.9% | -137.3% | -34.1% | -17.7% | -6.6% | -21.5% | -29.5% | -45.7% | -124.1% | -19.1% | -160.5% | N/A | N/A |
| Market Cap | 82M | 23M | 46M | 134M | 346M | 97M | 78M | 43M | 13M | 94M | 21M | 0 | 3.5M |
| Avg. Price | 358,135.46 | 123,098.21 | 24,177.05 | 12,156.89 | 3,594.60 | 902.75 | 168.30 | 202.27 | 32.85 | 22.02 | 12.48 | 0.00 | 0.49 |
| Year-End Price | 212,062.50 | 56,250.00 | 13,781.25 | 8,550.00 | 776.25 | 153.75 | 168.75 | 63.25 | 15.75 | 18.50 | 13.42 | 0.00 | 0.49 |
Traws Pharma, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
The Ledger Terminal provides 15 years of financial data for Traws Pharma, Inc. (TRAW), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Traws Pharma, Inc. (TRAW) has a book value per share of $-0.08, based on its most recent annual SEC filing.